Based on dynamic PET data, Albert et al. showed that the serum half-life of nanobody-based α-EGFR TMs slightly increased from 1.7 h to 7 h and 19.4 h for UniCAR- and tumor-bound TMs, respectively [57]. This evidence concerns the gene EGFR and neoplasm.